Merck & Co., Inc.

MRK

US58933Y1055

Pharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 11:02:08 2024-04-26 am EDT			5-day change	1st Jan Change
131.2 ^USD	+0.36%		+4.29%	+20.33%

04:48pm	Guggenheim Adjusts Price Target on Merck to $146 From $144	MT
04:37pm	Wells Fargo Adjusts Price Target on Merck & Company to $140 From $135	MT

Frank Clyburn to Leave Merck

January 20, 2022 at 06:45 am EST

Merck announced that Frank Clyburn, executive vice president and president, Human Health, will leave Merck on Feb. 1, 2022, to assume a leadership opportunity with another company. Leadership of Human Health following Frank's departure will be announced in the coming weeks.

Latest news about Merck & Co., Inc.

Guggenheim Adjusts Price Target on Merck to $146 From $144	10:48am	MT
Wells Fargo Adjusts Price Target on Merck & Company to $140 From $135	10:37am	MT
Deutsche Bank Adjusts Price Target on Merck & Company to $140 From $135	10:31am	MT
JPMorgan Chase Adjusts Price Target on Merck to $145 From $140	10:30am	MT
Goldman Sachs Raises Price Target on Merck & Company to $144 From $139	10:13am	MT
Leerink Partners Raises Price Target on Merck & Company to $136 From $132	09:14am	MT
Truist Lifts Price Target on Merck to $143 From $142, Keeps Buy Rating	07:44am	MT
AbbVie raises annual profit forecast on strong Skyrizi sales	07:36am	RE
Jefferies Adjusts Merck & Company Price Target to $150 From $145	07:19am	MT
Cantor Fitzgerald Adjusts Merck & Co.' Price Target to $155 From $135, Keeps Overweight Rating	Apr. 25	MT
Top Midday Stories: Shares of Meta, IBM, Caterpillar, Comcast and Southwest Down Big Post-Earnings; AstraZeneca Shares See Post-Earnings Bump	Apr. 25	MT
Global markets live: Ford, Dow, American Airlines, Comcast, Apple, IBM, Cisco...	Apr. 25
The specter of stagflation rears its ugly head again	Apr. 25
Transcript : Merck & Co., Inc., Q1 2024 Earnings Call, Apr 25, 2024	Apr. 25
Merck Lifts Full-Year 2024 Outlook Following First-Quarter Beat	Apr. 25	MT
Merck raises annual target ranges	Apr. 25	CF
Merck Non-GAAP Earnings, Sales Rise; 2024 Guidance Raised	Apr. 25	MT
(MRK) MERCK & CO. Expects Fiscal Year 2024 EPS Range $8.53 - $8.65	Apr. 25	MT
Earnings Flash (MRK) MERCK & CO. Reports Q1 Revenue $15.78B	Apr. 25	MT
Earnings Flash (MRK) MERCK & CO. Posts Q1 EPS $2.07	Apr. 25	MT
Merck & Co., Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 25	CI
Merck & Co., Inc. Provides Earnings Guidance for Full-Year 2024	Apr. 25	CI
Merck raises 2024 profit forecast on strong cancer, HPV drugs sales	Apr. 25	RE
Scholz promises support for pharma sector in Germany as Merck invests	Apr. 25	RE
Hipgnosis' bidding war intensifies as Concord hikes offer for Shakira music owner	Apr. 25	RE

Chart Merck & Co., Inc.

Duration

Period

More charts

Company Profile

Merck & Co., Inc. specializes in the development, production, and marketing of therapeutic products and vaccines sold under prescription. Net sales break down by activity as follows: - sale of pharmaceutical products (69.7%): for treating hypertension, osteoporosis, atherosclerosis, respiratory, bacterial and fungal, ophthalmologic, and urological diseases, acute migraine, hair loss in men, etc.; - sale of vaccines (18%); - sale of animal health products (9.4%); - other (2.9%). Net sales are distributed geographically as follows: the United States (45.9%), Europe/Middle East/Africa (24.5%), China (8.8%), Japan (6.1%), Asia/Pacific (6.1%), Latin America (4.3%) and other (4.3%).

Sector

Pharmaceuticals

Calendar

2024-05-28 - Annual General Meeting

Related indices

Dow Jones Industrial , S&P 500

More about the company

Income Statement Evolution

More financial data

Ratings for Merck & Co., Inc.

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

130.7 USD

Average target price

139.6 USD

Spread / Average Target

+6.78%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
MERCK & CO., INC.	+20.33%	331B
ELI LILLY AND COMPANY	+25.64%	653B
NOVO NORDISK A/S	+26.31%	556B
JOHNSON & JOHNSON	-6.55%	354B
ABBVIE INC.	+4.36%	296B
ASTRAZENECA PLC	+12.81%	233B
NOVARTIS AG	+5.48%	201B
ROCHE HOLDING AG	-9.57%	193B
AMGEN INC.	-6.21%	144B
PFIZER, INC.	-11.98%	143B

Other Pharmaceuticals

Merck & Co., Inc.

Equities

MRK

US58933Y1055

Pharmaceuticals

Frank Clyburn to Leave Merck

EPS Revisions